Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 453-459

  Tsukasaki, Kunihiro ^a   Hermine, Olivier ^a   Bazarbachi, Ali ^a   Ratner, Lee ^a   Ramos, Juan Carlos ^a   Harrington, William ^a   O'Mahony, Deirdre ^a   Janik, John E ^a   Bittencourt, Achiléa L ^a   Taylor, Graham P ^a   Yamaguchi, Kazunari ^a   Utsunomiya, Atae ^a   Tobinai, Kensei ^a   Watanabe, Toshiki ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PANOBINOSTAT; PREDNISONE; RANIMUSTINE; ROMIDEPSIN; TUMOR MARKER; VINCRISTINE; VINDESINE; VORINOSTAT;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; IMMUNE DEFICIENCY; INFECTION COMPLICATION; MULTIDRUG RESISTANCE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WATCHFUL WAITING;

ADULT; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; PROGNOSIS;

EID: 58549103931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.2428     Document Type: Article

References (61)

1. Uchiyama T, Yodoi J, Sagawa K, et al: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50:481-492, 1977
2. Poiesz BJ, Ruscetti FW, Gazdar AF, et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77:7415-7419, 1980
3. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79:2031-2035, 1982
4. Kikuchi M, Jaffe ES, Ralfkiaer E: Adult T-cell leukaemia/lymphoma, in Jaffe ES, Harris NL, Stein H, et al (eds): WHO Classification of Tumours; Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001, pp 200-203
5. Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative study- Lymphoma Study Group (1984-1987). Leuk Res 15:81-90, 1991
6. Takatsuki K: Adult T-Cell Leukemia. New York, NY, Oxford University Press, 1994
7. International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans: Human immunodeficiency viruses and human T-cell lymphotropic viruses. International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans. http://monographs.iarc.fr/ENG/Monographs/vol67/volume67.pdf
8. Tobinai K, Watanabe T: Adult T-cell leukemia-lymphoma, in Abeloff MD, Armitage JO, Niederhu- ber JE, et al (eds): Clinical Oncology (ed 3). Philadelphia, PA, Elsevier Churchill Livingstone, 2004, pp 3109-3130
9. Yamada Y, Hatta Y, Murata K, et al: Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia. J Clin Oncol 15:1778-1785, 1997
10. Utsunomiya A, Ishida T, Inagaki A, et al: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: A blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res 31:915-920, 2007
11. Takasaki Y, Iwanaga M, Tsukasaki K, et al: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31:751-757, 2007
12. Inagaki A, Ishida T, Ishii T, et al: Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: High interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 118:3054-3061, 2006
13. Ishida T, Utsunomiya A, Iida S, et al: Clinical significance of CCR4 expression in adult T-cell leu- kemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-3634, 2003
14. Ohno N, Tani A, Uozumi K, et al: Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 98: 1160-1165, 2001
15. Tawara M, Hogerzeil SJ, Yamada Y, et al: Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma. Cancer Lett 234:249-255, 2006
16. Tsukasaki K, Krebs J, Nagai K, et al: Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: Correlation with clinical course. Blood 97:3875-3881, 2001
17. Tsukasaki K, Imaizumi Y, Tawara M, et al: Diversity of leukaemic cell morphology in ATL correlates with prognostic factors, aberrant immuno-phenotype and defective HTLV-1 genotype. Br J Haematol 105:369-375, 1999
18. Bittencourt AL, da Gracas Vieira M, Brites CR, et al: Adult T-cell leukemia/lymphoma in Bahia, Brazil: Analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol 128:875-882, 2007
19. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia- lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991
20. Phillips AA, Shapira I, Willim RD, et al: A multicenter clinicopathologic experience of HTLV-1 ATLL: A retrospective 15 year review reveals little progress. Blood 110:1044a, 2007 (abstr 3569)
21. Hermine O, Panelatti G, Ramos JC, et al: A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma: 13th International Conference on Human Retrovirology, Hakone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007 (ab- str 106)
22. Bazarbachi A, Panelatti G, Ramos JC, et al: A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma: American Society of Hematol- ogy, Atlanta, Georgia, USA, 2007. Blood 110:610a- 611a, 2007 (abstr 2049)
23. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of chronic (mature) B and T lymphoid leukaemias: French-American-British (FAB) Cooperative Group. J Clin Pathol 42: 567-584, 1989
24. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004
25. Utsunomiya A, Hanada S, Terada A, et al: Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 61:824-828, 1988
26. Teshima T, Akashi K, Shibuya T, et al: Central nervous system involvement in adult T-cell leuke- mia/lymphoma. Cancer 65:327-332, 1990
27. Kamihira S, Atogami S, Sohda H, et al: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753-2758, 1994
28. Sadamori N, Ikeda S, Yamaguchi K, et al: Serum deoxythymidine kinase in adult T-cell leukemia- lymphoma and its related disorders. Leuk Res 15:99-103, 1991
29. Itoyama T, Chaganti RS, Yamada Y, et al: Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: A study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97:3612-3620, 2001
30. Oshiro A, Tagawa H, Ohshima K, et al: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107:4500-4507, 2006
31. Tsukasaki K, Tsushima H, Yamamura M, et al: Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: Frequent clonal change at crisis from indolent disease. Blood 89:948-956, 1997
32. Ramos JC, Ruiz P Jr, Ratner L, et al: IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109:3060-3068, 2007
33. Bazarbachi A, Ghez D, Lepelletier Y, et al: New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 5:664-672, 2004
34. Taylor GP, Matsuoka M: Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 24:6047-6057, 2005
35. Yamada Y, Murata K, Kamihira S, et al: Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. Cancer 67:2605-2609, 1991
36. Tsukasaki K, Utsunomiya A, Fukuda H, et al: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-5464, 2007
37. Tsukasaki K, Ikeda S, Murata K, et al: Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leuke-mia/lymphoma. Leuk Res 17:157-166, 1993
38. Gill PS, Harrington W Jr, Kaplan MH, et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med 332:1744-1748, 1995
39. Hermine O, Bouscary D, Gessain A, et al: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 332: 1749-1751, 1995
40. Bazarbachi A, Hermine O: Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 13:S186-S190, 1996 (suppl 1)
41. White JD, Wharfe G, Stewart DM, et al: The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 40:287-294, 2001
42. Matutes E, Taylor GP, Cavenagh J, et al: Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: Response and outcome in 15 patients. Br J Haematol 113:779-784, 2001
43. Hermine O, Allard I, Levy V, et al: A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 3:276-282, 2002
44. Datta A, Bellon M, Sinha-Datta U, et al: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 108:1021-1029, 2006
45. Takasaki Y, Tsukasaki K, Iwanaga M, et al: A long-term study of prognosis in indolent types of adult T-cell leukemia/lymphoma (ATLL): 13th International Conference on Human Retrovirology, Ha- kone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007 (abstr 208)
46. Fukushima T, Miyazaki Y, Honda S, et al: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 5:829-834, 2005
47. Okamura J, Utsunomiya A, Tanosaki R, et al: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105:4143-4145, 2005
48. Yamaguchi K, Matutes E, Catovsky D, et al: Strongyloides stercoralis as candidate co-factor for HTLV-I-induced leukaemogenesis. Lancet 2:94-95, 1987
49. Gabet AS, Mortreux F, Talarmin A, et al: High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis. Oncogene 19:4954-4960, 2000
50. Satoh M, Toma H, Sugahara K, et al: Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene 21:2466-2475, 2002
51. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
52. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
53. Cheson BD, Pfistner B, Juweid ME, et al: The International Harmonization Project on Lymphoma: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
54. Bazarbachi A, El Sabban M, Nasr R, et al: Arsenic trioxide and interferon alpha synergize to induce cell cycle arrest and apoptosis in HTLV-I transformed cells. Blood 93:278-283, 1999
55. El-Sabban M, Nasr R, Dbaibo G, et al: Arsenic- interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with Tax downregulation and reversal of NF-kappa B activation. Blood 96: 2849-2855, 2000
56. Nasr R, Rosenwald A, El-Sabban ME, et al: Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-I infected leukemic cells. Blood 101:4576-4582, 2003
57. Hermine O, Dombret H, Poupon J, et al: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leu-kemia/lymphoma. Hematol J 5:130-134, 2004
58. Nasr R, El-Sabban M, Karam J, et al: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 24: 419-430, 2005
59. El-Sabban M, Abu Merhi R, Abi Haidar H, et al: Human T-cell lymphotropic virus type I transformed cells induce angiogenesis and establish functional gap junctions with endothelial cells. Blood 99:3383-3389, 2002
60. Moura IC, Lepelletier Y, Arnulf B, et al: A neutralizing monoclonal antibody (mAb A24) directed against the transferring receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103:1838-1845, 2004
61. Pise-Masison CA, Radonovich MA, Dohoney KA, et al: Gene expression profiling of ATL Patients: Identification of signaling pathways which contribute to ATL-13th International Conference on Human Retrovirology, Hakone, Japan, 2007. AIDS Res Hum Retroviruses 23:597-598, 2007 (abstr 307)